Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.

Diagn Pathol · 2014 · PMC4251942 · PMID 25421173

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

As shown in Table 2 , the results of overall response rate (RR = 1.65, 95% CI: 0.99-2.75) and 1-year survival rate (RR = 1.35, 95% CI: 0.98-1.86) were marginally significant, and it was highly possible that the results of response and 1-year survival would be statistically significant when further trials are reported.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.